Hypertriglyceridemia and risk of coronary heart disease

Current Cardiology Reports

Volumn 4, Issue 6, 2002, Pages 488-493

  Hokanson, John E ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOPROTEIN;

BLOOD; COMORBIDITY; CORONARY ARTERY DISEASE; HUMAN; HYPERTRIGLYCERIDEMIA; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; RISK FACTOR;

COMORBIDITY; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERTRIGLYCERIDEMIA; LIPOPROTEINS; METABOLIC SYNDROME X; RISK FACTORS;

EID: 0036832760     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-002-0112-7     Document Type: Article

References (28)

1. Gofman JW, DeLalla O, Flazier F, et al.: The serum lipoprotein transport system in health, metabolic disorders, atherosclerosis, and coronary disease. Plasma 1954, 2:413-483.
2. Albrink M, Mann E: Serum triglycerides in coronary artery disease. Arch Intern Med 1959, 103:4-8.
3. Brown DF, Kinch SH, Doyle JT: Serum triglycerides in health and in ischemic heart disease. N Engl J Med 1965, 273:947-952.
4. Hulley SB, Rosenman RH, Bawol RD, Brand RJ: Epidemiology as a guide to clinical decisions. The association between triglyceride and coronary heart disease. N Engl J Med 1980, 302:1383-1389.
5. Hokanson JE, Austin MA: Plasma triglyceride is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of populationbased prospective studies. J Cardiovasc Risk 1996, 3:213-219.
6. Abdel-Maksoud MF, Hokanson JE: The complex role of triglyceride in cardiovascular disease: both independence and synergy with HDL cholesterol. Semin Vasc Med 2002, 2:325-333.
7. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F: Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation 1998, 97:1029-1036.
8. Assmann G, Schulte H, Funke H, von Eckardstein A: The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J 1998, 19(Suppl M):M8-M14.
9. Onat A, Sansoy V, Yildirim B: Which fasting triglyceride levels best reflect coronary risk? Evidence from the Turkish Adult Risk Factor Study. Clin Cardiol 2001, 24:9-14.
10. Cambien F, Jacqueson A, Richard JL, et al.: Is the level of serum triglyceride a significant predictor of coronary death in " normocholesterolemic" subjects? The Paris Prospective Study. Am J Epidemiol 1986, 124:624-632.
11. Criqui MH, Heiss G, Cohn R, et al.: Plasma triglyceride level and mortality from coronary heart disease. N Engl J Med 1993, 328:1220-1225.
12. Rhoads GG, Feinleib M: Serum triglyceride and risk of coronary heart disease, stroke, and total mortality in Japanese-American men. Arteriosclerosis 1983, 3:316-322.
13. Heyden S, Heiss G, Hames CG, Bartel AG: Fasting triglycerides as predictors of total and CHD mortality in Evans County, Georgia. J Chronic Dis 1980, 33:275-282.
14. Iso H, Naito Y, Sato S, et al.: Serum triglycerides and risk of coronary heart disease among Japanese men and women. Am J Epidemiol 2001, 153:490-499.
15. Sharrett AR, Ballantyne CM, Coady SA, et al.: Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2001, 104:1108-1113.
16. Brunzell JD, Albers JJ, Chait A, et al.: Plasma lipoproteins in familial combined hyperlipidemia and monogenic familial hypertriglyceridemia. J Lipid Res 1983, 24:147-155.
17. Gofman JW, Young W, Tandy R: Ischemic heart disease, atherosclerosis, and longevity. Circulation 1966, 34:679-697.
18. Castelli WP: Epidemiology of triglycerides: a view from Framingham. Am J Cardiol 1992, 70:3H-9H.
19. Brunzell JD, Schrott HG, Motulsky AG, Bierman EL: Myocardial infarction in the familial forms of hypertriglyceridemia. Metabolism 1976, 25:313-320.
20. Austin MA, McKnight B, Edwards KL, et al.: Cardiovascular disease mortality in familial forms of hypertriglyceridemia: a 20-year prospective study. Circulation 2000, 101:2777-2782.
21. Austin M, King M-C, Vranizan K, Krauss RM: The atherogenic lipoprotein phenotype (ALP): a proposed genetic marker for coronary heart disease risk. Circulation 1990, 82:495-506.
22. Hokanson JE, Brunzell JD, Jarvik GP, et al.: Linkage of lowdensity lipoprotein size to the lipoprotein lipase gene in heterozygous lipoprotein lipase deficiency. Am J Hum Genet 1999, 64:608-618.
23. Hokanson JE: Functional variants in the lipoprotein lipase gene and risk cardiovascular disease. Curr Opin Lipidol 1999, 10:393-399.
24. McGarry JD: Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 2002, 51:7-18.
25. Holzl B, Iglseder B, Sandhofer A, et al.: Insulin sensitivity is impaired in heterozygous carriers of lipoprotein lipase deficiency. Diabetologia 2002, 45:378-384.
26. Pfeifer MA, Brunzell JD, Best JD, et al.: The response of plasma triglyceride, cholesterol, and lipoprotein lipase to treatment in non-insulin-dependent diabetic subjects without familial hypertriglyceridemia. Diabetes 1983, 32:525-531.
27. Junker R, Pieke B, Schulte H, et al.: Changes in hemostasis during treatment of hypertriglyceridemia with a diet rich in monounsaturated and n-3 polyunsaturated fatty acids in comparison with a low-fat diet. Thromb Res 2001, 101:355-366.
28. Jonkers IJ, Mohrschladt MF, Westendorp RG, et al.: Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial. Am J Med 2002, 112:275-280.